Skip to main content

Table 4 Tests for heterogeneity of treatment effect according to the clinicopathological characteristics of the patients undergoing gastrectomy with and without splenectomy

From: Is concomitant splenectomy beneficial for the long-term survival of patients with gastric cancer undergoing curative gastrectomy? A single-institution study

Subgroup G + S, patients/total patients, n G-A, patients/total patients, n HR (95% CI)a P-valueb
Deaths 87/100 83/114 1.456 (1.076 to 1.970)  
Age, years     
  ≤ 55 26/32 25/38 1.559 (0.897 to 2.709) 0.116
  > 55 61/68 58/76 1.377 (0.960 to 1.974) 0.082
Sex     
 Women 17/18 20/29 1.527 (0.797 to 2.926) 0.201
 Men 70/82 63/85 1.433 (1.018 to 2.018) 0.039c
Tumor size, cm     
  ≤ 4 16/23 15/27 1.606 (0.778 to 3.314) 0.200
 5 to 6 23/26 18/21 1.135 (0.604 to 2.134) 0.694
  > 6 48/51 50/66 1.606 (1.079 to 2.391) 0.019c
Pathological tumor stage     
 T1 5/5 7/8 3.458 (0.790 to 15.144) 0.100
 T2 21/28 30/45 1.478 (0.840 to 2.598) 0.175
 T3 14/16 19/26 0.871 (0.426 to 1.781) 0.706
 T4 7/8 4/6 1.803 (0.521 to 6.238) 0.352
Pathological nodal stage     
 N0 7/10 15/24 1.800 (0.707 to 4.586) 0.218
 N1 16/20 19/29 1.373 (0.704 to 2.678) 0.353
 N2 21/23 19/23 1.221 (0.648 to 2.300) 0.537
 N3 11/12 7/9 0.969 (0.345 to 2.722) 0.952
TNM stage     
 IA 2/2 5/5 2.783 (0.386 to 20.066) 0.310
 IB 16/19 14/23 1.433 (0.694 to 2.961) 0.331
 II 15/18 21/30 1.875 (0.955 to 3.681) 0.068
 IIIA 23/29 22/31 1.027 (0.567 to 1.860) 0.930
 IIIB 13/14 13/14 0.800 (0.359 to 1.783) 0.585
 IV 18/18 8/11 1.649 (0.706 to 3.850) 0.248
Gross type (Borrmann)     
 I 2/3 2/2 1.405 (0.125 to 15.838) 0.783
 II 18/20 7/12 1.908 (0.790 to 4.609) 0.151
 III 50/59 46/66 1.536 (1.028 to 2.296) 0.036c
 IV 16/17 23/29 1.623 (0.847 to 3.111) 0.145
Type of gastrectomy     
 Total 53/60 50/68 1.317 (0.893 to 1.942) 0.165
 Sub-total 34/40 33/46 1.700 (1.032 to 2.803) 0.037c
  1. Abbreviations: G + S gastrectomy plus splenectomy, G-A gastrectomy alone, HR hazard ratio, TNM tumor, node, metastasis.
  2. aHR >1 indicates that G-A was superior, whereas HR <1 indicates that G + S was superior.
  3. bThe P-values are for HRs for deaths in each group (G + S or GA), with 95% CI.
  4. cConsidered significantly better for G + S.